Tag Archive for: Cancer

ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

/in

Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1) Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months Improved tumour infiltration by immune cells predicted response to therapy Oegstgeest, March 1, 2022 – ISA today announces the publication of […]

Read more

ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022

/in

Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals will be attending the following in person scientific and business conferences from February through to April 2022 (subject to travel restrictions), in addition to virtual conferences. Read more…

Read more

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

/in

Promising non-clinical results support Phase 1 clinical study in recurrent GBM Commitment to ensuring I-123 PARPi is available to treat the unmet medical need of patients diagnosed with primary and recurrent GBM LONDON, UK, 10 February 2022 – Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 […]

Read more

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

/in

Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers.  Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials. Cambridge, UK, 26 January 2022 – CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat […]

Read more

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

/in

Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific Officer, Cornelis “Kees” Melief, M.D., Ph.D., will be presenting key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online. Read more…

Read more